Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
about
Combining radiotherapy with sunitinib: lessons (to be) learnedRadiotherapy and "new" drugs-new side effects?Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastasesNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Targeting immune suppressing myeloid-derived suppressor cells in oncology.Radical irradiation of extracranial oligometastases.Updates on the management of gastrointestinal stromal tumors.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.Advances in the targeted therapy of liposarcoma.Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancerA phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation OncologyImmune microenvironments in solid tumors: new targets for therapy.Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review.Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body RadiotherapyPhase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcomaMulticenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.Stereotactic body radiotherapy treatment of extracranial metastases.Microenvironment and radiation therapyTo combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reductionThe development of stereotactic body radiotherapy in the past decade: a global perspective.Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report.SBRT for lung oligometastases: Who is the perfect candidate?Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesisAblation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.Radiotherapy in combination with vascular-targeted therapies.Treatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma.Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.The oligometastatic state - separating truth from wishful thinking.Radiotherapy for Gastrointestinal Stromal Tumors.The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.
P2860
Q26800587-495A72B2-2921-47D6-B054-15FEA9703695Q26861498-48FBFACE-9FD8-4D68-9173-84A917A05818Q28727917-2722554E-0E9C-4606-945C-794ABF3F2113Q33921067-722A6A65-7486-4C87-B8BE-96CB5D784601Q34082067-EAD9B80C-ABFF-4212-8D21-51CABBF9C844Q34124296-FEBAFEAC-D3FF-43DA-804F-1C8C073D5AABQ34256921-B911D360-8CFB-4C12-85C3-A68A8272C15AQ34396047-5D0C44B0-CAE9-440B-BC41-9237C37CD06AQ34461532-1C096623-C637-40BD-9058-AA4848F418E6Q34952133-054873F4-86B4-4B6F-876A-FB5EE19C3141Q35117298-97DB0FE2-D249-4267-BB5C-2FD8B0DF0BF8Q35121736-8A9AC7EA-50F6-4331-A677-43E15A123130Q35207344-0470AE23-7DF2-43C7-847E-EE5F0A9AAD68Q35496632-543D9C13-3A22-4A9E-BDF6-3D12A98034EEQ35642044-4108302D-657F-45B3-9D17-8DCB711B20E4Q36360066-D2935C00-5B2C-4858-AAE6-ED09155E91E1Q36483105-D6FDEF71-B8D0-4815-B236-4E830B106551Q37190323-62508AE6-C88D-47D2-AB47-C2C7EB248284Q37333673-4C6CEE55-AD5D-4A5E-BD47-B2A75EFFF1C6Q37997734-42A12521-06C6-40ED-A80C-D6B4A4E68116Q38046079-E9A10305-05E2-41DC-A419-AB11C2BB89C7Q38091084-BFA4CDA3-D71B-4751-A6D5-00C2994A0142Q38105006-6F0DF225-D57A-49F7-A082-2789A8C50B17Q38172209-A903837B-A804-4B49-BC32-9A811BA0BA8AQ38892371-1696E864-9902-4000-9B1D-368B92E46AA3Q38967475-11AF5FA9-003A-47DA-95B1-91B27076C828Q39252570-5D8F534D-B458-45AA-8B87-AAE86A3EB64AQ40179018-7A45506B-12EF-45F6-95F4-F564053ACE98Q41150956-A96882CF-6BBB-4612-BB02-90F5433974E3Q42109042-7F4D952A-57E3-4AAB-A4DA-56B7F842E5A9Q42203737-DAF54EB8-4CB5-4DB6-864E-97C312A62E20Q42427607-0C378CAF-9DCB-4BBC-BD9B-DB6592415AB7Q43179458-EEB4DB40-860E-489D-9BE7-3291A439A99AQ46288612-8CB03563-E707-42C2-8FD3-3D0B7DAF1464Q48536660-E4D966B1-74FC-4A46-AE33-CAF43947F59FQ50537326-E0576AE1-3BCB-464F-89C7-60BE2B40BFA4Q52591818-ECC6FB73-4CC9-4536-A994-D714650C4676Q54942438-FD376CC9-5DEC-42C4-A7AA-3D9B56F329CC
P2860
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase 1 study of concurrent su ...... city and preliminary response.
@ast
Phase 1 study of concurrent su ...... city and preliminary response.
@en
type
label
Phase 1 study of concurrent su ...... city and preliminary response.
@ast
Phase 1 study of concurrent su ...... city and preliminary response.
@en
prefLabel
Phase 1 study of concurrent su ...... city and preliminary response.
@ast
Phase 1 study of concurrent su ...... city and preliminary response.
@en
P2093
P2860
P356
P1433
P1476
Phase 1 study of concurrent su ...... city and preliminary response.
@en
P2093
Delphine Huang
Ha Linh Vu
Jamie A Cesaretti
Johnny Kao
Max W Sung
Myron E Schwartz
Richard G Stock
Shu-Hsia Chen
Stuart Packer
Yeh-Chi Lo
P2860
P304
P356
10.1002/CNCR.24412
P407
P577
2009-08-01T00:00:00Z